Furthermore, there were no statistically significant differences between the two groups of participants in median age, sex-stratified BMI, mean arterial pressure (MAP), duration of follow-up, viral load, CD4+ count, serum creatinine, fasting blood glucose (FBG), eGFR, serum cholesterol, urine creatinine, urine albumin-to-creatinine ratio, Kidney Disease: Improving Global Outcomes (KDIGO) stage of kidney dysfunction, and urine phosphate-to-creatinine ratio (Table 1). The gene discussed is ALB; the disease is kidney disorder.